Trade Theravance Biopharma, Inc. - TBPH CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 9.18 |
| Open | 9.09 |
| 1-Year Change | -21.09% |
| Day's Range | 9.03 - 9.22 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2024 | 9.18 | -0.16 | -1.71% | 9.34 | 9.56 | 9.15 |
| Apr 22, 2024 | 9.41 | 0.11 | 1.18% | 9.30 | 9.43 | 9.11 |
| Apr 19, 2024 | 9.30 | 0.27 | 2.99% | 9.03 | 9.34 | 8.94 |
| Apr 18, 2024 | 9.15 | -0.29 | -3.07% | 9.44 | 9.46 | 9.13 |
| Apr 17, 2024 | 9.46 | -0.16 | -1.66% | 9.62 | 9.80 | 9.44 |
| Apr 16, 2024 | 9.62 | -0.05 | -0.52% | 9.67 | 9.83 | 9.52 |
| Apr 15, 2024 | 9.84 | 0.41 | 4.35% | 9.43 | 9.94 | 9.39 |
| Apr 12, 2024 | 9.57 | 0.12 | 1.27% | 9.45 | 10.34 | 9.35 |
| Apr 11, 2024 | 8.83 | -0.59 | -6.26% | 9.42 | 9.47 | 8.73 |
| Apr 10, 2024 | 9.49 | 0.26 | 2.82% | 9.23 | 9.52 | 9.12 |
| Apr 9, 2024 | 9.45 | 0.20 | 2.16% | 9.25 | 9.58 | 9.25 |
| Apr 8, 2024 | 9.43 | 0.44 | 4.89% | 8.99 | 9.47 | 8.99 |
| Apr 5, 2024 | 9.26 | 0.23 | 2.55% | 9.03 | 9.29 | 8.99 |
| Apr 4, 2024 | 9.08 | -0.08 | -0.87% | 9.16 | 9.36 | 9.01 |
| Apr 3, 2024 | 9.25 | 0.24 | 2.66% | 9.01 | 9.28 | 8.92 |
| Apr 2, 2024 | 9.07 | 0.40 | 4.61% | 8.67 | 9.08 | 8.67 |
| Apr 1, 2024 | 8.98 | 0.10 | 1.13% | 8.88 | 9.00 | 8.68 |
| Mar 28, 2024 | 8.94 | 0.06 | 0.68% | 8.88 | 8.97 | 8.72 |
| Mar 27, 2024 | 8.97 | 0.15 | 1.70% | 8.82 | 8.98 | 8.73 |
| Mar 26, 2024 | 8.75 | 0.03 | 0.34% | 8.72 | 8.91 | 8.68 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Theravance Biopharma, Inc. Company profile
About Theravance Biopharma Inc
Theravance Biopharma, Inc. is a diversified biopharmaceutical company, which is primarily focused on the discovery, development and commercialization of organ-selective medicines. The Company develops transformational medicines to improve the lives of patients suffering from serious illnesses. The Company's research is focused in the areas of inflammation and immunology. It applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The Company is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Theravance Biopharma Inc revenues decreased 23% to $55.3M. Net loss decreased 28% to $199.4M. Revenues reflect U.S. segment decrease of 21% to $55.3M, Europe segment decrease of 98% to $38K. Lower net loss reflects Research and development - bal decrease of 27% to $166.6M (expense), Selling, general and administrative -bal decrease of 55% to $31M (expense).
| Industry: | Pharmaceuticals (NEC) |
Ugland House, South Church Street
GEORGE TOWN
GRAND CAYMAN KY1-1104
KY
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com